CR20140135A - Nuevos derivados de aril-quinolina - Google Patents

Nuevos derivados de aril-quinolina

Info

Publication number
CR20140135A
CR20140135A CR20140135A CR20140135A CR20140135A CR 20140135 A CR20140135 A CR 20140135A CR 20140135 A CR20140135 A CR 20140135A CR 20140135 A CR20140135 A CR 20140135A CR 20140135 A CR20140135 A CR 20140135A
Authority
CR
Costa Rica
Prior art keywords
quinolina
aril
new derivatives
compounds
derivatives
Prior art date
Application number
CR20140135A
Other languages
English (en)
Inventor
Simona M Ceccarelli
Aurelia Conte
Holger Kuehne
Bernd Kuhn
Werner Neidhart
Sander Ulrike Obst
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20140135A publication Critical patent/CR20140135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La invención proporciona nuevos compuestos, que tienen la fórmula general (I) en la que R1, R2, R3, R4, R5, R6 y n tienen los significados aquí definidos, composiciones que incluyen estos compuestos y métodos de utilización de estos compuestos.
CR20140135A 2011-11-04 2014-03-24 Nuevos derivados de aril-quinolina CR20140135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187967 2011-11-04

Publications (1)

Publication Number Publication Date
CR20140135A true CR20140135A (es) 2014-06-19

Family

ID=47115939

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140135A CR20140135A (es) 2011-11-04 2014-03-24 Nuevos derivados de aril-quinolina

Country Status (21)

Country Link
US (2) US9199938B2 (es)
EP (1) EP2773619B1 (es)
JP (1) JP6170060B2 (es)
KR (1) KR20140088194A (es)
CN (1) CN103906735B (es)
AR (1) AR088625A1 (es)
AU (1) AU2012331289B2 (es)
BR (1) BR112014010644A2 (es)
CA (1) CA2849945A1 (es)
CL (1) CL2014001060A1 (es)
CO (1) CO6930359A2 (es)
CR (1) CR20140135A (es)
EA (1) EA201490846A1 (es)
ES (1) ES2609773T3 (es)
IL (1) IL231950B (es)
MX (1) MX343893B (es)
MY (1) MY169267A (es)
PE (1) PE20142282A1 (es)
SG (1) SG11201401937YA (es)
TW (1) TWI616437B (es)
WO (1) WO2013064465A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343893B (es) 2011-11-04 2016-11-28 Hoffmann La Roche Nuevos derivados de aril-quinolina.
KR20150046056A (ko) * 2012-08-24 2015-04-29 에프. 호프만-라 로슈 아게 신규한 바이사이클릭피리딘 유도체
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2017184547A1 (en) 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
EP3246028A1 (en) * 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
EP3535253A1 (en) 2016-11-01 2019-09-11 H. Hoffnabb-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
CN107311847B (zh) * 2017-07-12 2020-11-10 安徽省诚联医药科技有限公司 5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法
CN109280028B (zh) * 2017-07-19 2022-03-25 上海医药工业研究院 喹啉类化合物及其在dpp-4酶抑制剂的应用
BR112020022619A2 (pt) 2018-05-09 2021-02-02 Bayer Animal Health Gmbh novos derivados de quinolina
WO2020227331A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical entities, pharmaceutical formulations, and methods for treating fibrosis
CN113277978B (zh) * 2021-06-02 2022-06-03 河南师范大学 一种2，4-双取代喹啉类化合物的制备方法
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
TW205037B (es) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
JP3724818B2 (ja) * 1992-09-04 2005-12-07 武田薬品工業株式会社 縮合複素環化合物、その製造法および剤
JPH0769890A (ja) * 1993-06-29 1995-03-14 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬組成物
JPH08225531A (ja) * 1994-03-08 1996-09-03 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬およびそれに用いる新規誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2003265382A1 (en) * 2002-08-23 2004-03-11 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
KR101154431B1 (ko) * 2002-11-29 2012-06-15 주식회사 씨앤드씨신약연구소 치환된 1h-피리딘-2-온 유도체
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
NZ544697A (en) * 2003-07-22 2009-03-31 Janssen Pharmaceutica Nv Quinolinone derivatives as inhibitors of c-fms kinase
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2195296A1 (en) 2007-09-27 2010-06-16 F. Hoffmann-Roche AG Quinoline derivatives as 5ht5a receptor antagonists
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
GB0818365D0 (en) 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
US8815875B2 (en) * 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
WO2010056865A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
MX343893B (es) 2011-11-04 2016-11-28 Hoffmann La Roche Nuevos derivados de aril-quinolina.
CN104039786A (zh) 2011-11-04 2014-09-10 阿弗拉克西斯控股股份有限公司 用于治疗脆性x综合征的pak抑制剂
JP2015501327A (ja) 2011-11-04 2015-01-15 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺虫化合物

Also Published As

Publication number Publication date
CN103906735A (zh) 2014-07-02
SG11201401937YA (en) 2014-05-29
ES2609773T3 (es) 2017-04-24
AR088625A1 (es) 2014-06-25
AU2012331289A1 (en) 2014-04-10
EP2773619A1 (en) 2014-09-10
EA201490846A1 (ru) 2014-07-30
NZ622717A (en) 2016-06-24
PE20142282A1 (es) 2015-01-08
WO2013064465A1 (en) 2013-05-10
CO6930359A2 (es) 2014-04-28
US9809599B2 (en) 2017-11-07
TWI616437B (zh) 2018-03-01
TW201326130A (zh) 2013-07-01
CN103906735B (zh) 2016-12-07
JP2014532681A (ja) 2014-12-08
NZ720278A (en) 2017-08-25
AU2012331289B2 (en) 2017-07-13
MX343893B (es) 2016-11-28
BR112014010644A2 (pt) 2017-04-25
MY169267A (en) 2019-03-20
CA2849945A1 (en) 2013-05-10
IL231950B (en) 2018-02-28
KR20140088194A (ko) 2014-07-09
US9199938B2 (en) 2015-12-01
JP6170060B2 (ja) 2017-07-26
EP2773619B1 (en) 2016-11-16
CL2014001060A1 (es) 2014-11-07
US20130116234A1 (en) 2013-05-09
US20160060270A1 (en) 2016-03-03
MX2014005373A (es) 2014-07-30

Similar Documents

Publication Publication Date Title
CR20140135A (es) Nuevos derivados de aril-quinolina
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CR20160419A (es) Nuevos compuestos biciclicos
EA201590534A1 (ru) Новые бициклические производные
CR20140275A (es) Triazolopiridinas sustituidas
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
CR11861A (es) Compuestos organicos
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201290642A1 (ru) Соединения и способы
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201400058A1 (ru) Соединения и композиции на основе амидопиридиловых эфиров и их применение против паразитов
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia